CAR T cells – the immunotherapy of the future for lymphoma and leukemia
with Gunilla Enblad, professor at Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology at Uppsala University.
Acquire new knowledge about the latest discoveries in immune-oncology – the premise of CAR-T immunotherapy! Listen to an in depth talk about how scientists harvest T cells from people, genetically alter them to add a chimeric antigen receptor (CAR) that specifically recognizes cancer cells and hen infuse the resulting CAR-T cells into patients to attack their tumors.
Harvesting human cells is not an easy task! Join us to learn what are the biggest challenges for the researchers and what future steps are necessary to be made. Be part of the latest Efter Jobbet and the future of cancer treatment!
When: 28th of May 16.30-18.00. Coffee and sandwiches will be served.
Where: Uppsala Innovation Hub, Dag Hammarskjölds väg 38
*Please note that the presentation will be held in Swedish. Please contact us if you prefer English.
We asked Gunilla 3 short questions
- What is CarT cell treatment?
Genetically modified own T cells.
- Which patients are treated with CarT?
Patients with some lymphoma and leukemia who have no other curative treatment.
- What are the challenges of the treatment?
New side effects are included that are not so well-known in the healthcare system.
Nina Englund. Event coordinator. “My goal is that our partners and members get the very best experience when they meet and network at Uppsala BIO’s events.”